Mkaya Mwamburi, MD, PhD, MA, president and CEO of the biotechnology consulting firm profecyINTEL, said in a presentation at the 2017 SMi Biosimilar North America conference that manufacturers of originator biologics are taking the lead on biosimilar development.
Mkaya Mwamburi, MD, PhD, MA, president and CEO of the biotechnology consulting firm profecyINTEL, said in a presentation at the 2017 SMi Biosimilar North America conference that manufacturers of originator biologics are taking the lead on biosimilar development.
With a US market that Mwamburi says is currently valued at $5.2 billion—and is projected to reach $28.2 billion by 2020—biosimilars are becoming a more attractive investment opportunity for reference product sponsors. While makers of originator products have thus far attempted to retain market share through a variety of defensive strategies—“We’ve seen this through legal barriers being raised, and extensions of patent protection,” said Mwamburi—the coming patent cliff has forced sponsors to think about what Mwamburi calls “bi-vesting,” or diversifying revenue streams by moving into the biosimilars space. The future of biologic therapies, said Mwamburi, “…is going to involve a lot of buying, selling, and licensing between companies.”
An originator developer’s investment in biosimilars can involve 1 of 3 strategies for sharing risk and revenue: acquiring a biosimilar company, entering into a partnership with a biosimilar developer, or entering into a licensing partnership on a regional or global scale. He highlighted partnerships and acquisitions involving Pfizer—Celltrion, Novartis–Sandoz, and Amgen–Allergan as representatives of the emerging “symbiotic dynamic.”
Whether they occupy the originator biologic or biosimilar space, drug makers should carefully consider the value that they bring to a potential partnership before solidifying a deal, said Mwamburi.
Originator biologics developers’ considerations should include the following:
Biosimilar developers open to acquisition or partnership should:
Mwamburi sees the growing trend of investment on both sides of the reference and biosimilar divide as a positive trend for the industry; “Any variations in how [the legal] tug-of-war is going to happen is going to quickly stabilize” as drug makers learn how best to approach the issue of biosimilar market entry. He foresees patent negotiations eventually moving more quickly, and predicts that there will be more drug companies engaging in faster, less costly negotiations instead of litigation. “With those barriers getting out of the way, you’ll find the influx of biosimilars coming in.”
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.